Pregnancy Cholestasis: Causes, Symptoms, Diagnosis, and Evidence‑Based Treatment with Ursodeoxycholic Acid

Pregnancy cholestasis (also known as cholestasis of pregnancy) is a liver disorder that emerges in the second half of pregnancy. It is characterized by intense itching, elevated serum bile acids, and increased risk for both mother and fetus. Although rare, its prevalence varies widely across regions, and it can lead to serious complications such as preterm birth, fetal distress, and stillbirth. This article provides a comprehensive, evidence‑based overview of pregnancy cholestasis, including risk factors, pathophysiology, clinical presentation, diagnostic work‑up, and the current gold‑standard treatment with ursodeoxycholic acid (UDCA).

What Is Pregnancy Cholestasis?

First described by Ahlfeld in 1883, pregnancy cholestasis is the most common liver disease associated with pregnancy. It typically presents after 20 weeks of gestation and is marked by pruritus that often worsens at night and may involve the palms and soles. The hallmark laboratory finding is a marked elevation of total serum bile acids, often exceeding 40 µmol/L, which correlates with fetal risk.

Prevalence and Geographic Variation

United States: 1 in 1,000 to 3 in 1,000 pregnancies
United Kingdom: 7 in 1,000
Scandinavia: 1–2 % of pregnancies
Chile: up to 15 % in some studies
Low reporting in Sweden, France, and the U.S. due to underdiagnosis

Risk Factors

Several factors increase the likelihood of developing pregnancy cholestasis:

History of cholestasis in a prior pregnancy
Twin or higher‑order multiple gestations (20–22 % incidence)
Assisted reproductive technologies (2.7 % incidence)
Maternal age >35 years
Hepatitis C infection
Personal or family history of gallstones

Pathophysiology: A Multifactorial Interaction

Pregnancy cholestasis results from a complex interplay of genetic, hormonal, environmental, and nutritional factors:

Genetics: Mutations in genes encoding bile‑acid transporters (e.g., ABCB4, ABCB11) impair bile flow, leading to intrahepatic accumulation.
Hormonal: Elevated estrogen and progesterone levels in late pregnancy alter bile‑acid transport and reduce gallbladder motility.
Nutritional: Selenium deficiency has been linked to increased cholestasis risk due to its role as a cofactor for hepatic enzymes.
Environmental: Exposure to certain toxins or medications can exacerbate bile‑acid secretion.

Clinical Presentation and Symptoms

The most common symptom is generalized pruritus, often appearing before any laboratory abnormalities. Key points include:

Itching may be diffuse or localized to palms and soles.
It typically intensifies at night.
Only about 10 % of affected women develop jaundice.
In multiples, pruritus can appear as early as the first trimester.

Diagnostic Work‑Up

Laboratory Tests

Diagnosis is confirmed by:

Elevated total serum bile acids (≥10 µmol/L; severe if >40 µmol/L).
Transaminases (ALT/AST) 2–10× upper limit of normal; ALT may rise up to 10×.
Increased gamma‑glutamyl transferase (GGT) in ~50 % of cases.
Normal bilirubin in most patients; hyperbilirubinemia in 10–20 %.

Imaging

Abdominal ultrasound is performed to rule out gallstones or biliary obstruction, but is not diagnostic for cholestasis.

Differential Diagnosis

Viral hepatitis
HELLP syndrome
Acute fatty liver of pregnancy
Autoimmune hepatitis

Maternal and Fetal Outcomes

Maternal Effects

After delivery, liver enzymes and bile acids usually normalize within days. Persistent elevation suggests an underlying liver disease. Post‑partum use of combined oral contraceptives may trigger recurrence.

Fetal Risks

Risk increases with bile‑acid concentration:

Premature delivery (often after 37 weeks)
Meconium‑stained amniotic fluid (16–58 % vs. 15 % in normal pregnancies)
Fetal distress and intra‑uterine growth restriction
Stillbirth (historically 10–15 %; now ~3.5 % with modern management)

Early delivery (37–38 weeks) is often recommended to mitigate fetal risk, especially when bile acids exceed 40 µmol/L.

Treatment: Ursodeoxycholic Acid (UDCA)

UDCA is the first‑line therapy for pregnancy cholestasis. It is a naturally occurring bile acid that:

Reduces serum bile‑acid concentration by promoting enterohepatic circulation.
Protects hepatocytes and cholangiocytes from bile‑acid toxicity.
Has no significant adverse effects on the fetus or mother.

Typical dosing is 10–15 mg/kg/day, divided into two or three doses. Clinical trials demonstrate significant improvement in pruritus and a trend toward reduced preterm birth and stillbirth, although definitive fetal benefit remains under investigation.

Other Therapies

Colestyramine: Effective for itching but may impair vitamin K absorption, increasing bleeding risk.
Antihistamines: Provide symptomatic relief but do not lower bile acids.
Vitamin K supplementation: Recommended if prolonged cholestasis or high bile acids persist.

Monitoring and Follow‑Up

Pregnancy cholestasis is a high‑risk pregnancy. Management includes:

Weekly or bi‑weekly bile‑acid and liver enzyme checks.
Serial ultrasounds to assess fetal growth.
Non‑stress tests (NST) and biophysical profiles (BPP) after 32 weeks.
Early delivery planning (37–38 weeks) if bile acids >40 µmol/L or if fetal distress develops.

Frequently Asked Questions

1. Can pregnancy cholestasis recur in future pregnancies?

Yes. The recurrence rate is estimated at 45–70 %. Women with a history of cholestasis should be monitored closely in subsequent pregnancies.

2. Is UDCA safe for the fetus?

Multiple studies have shown no teratogenic effects. UDCA is considered safe throughout pregnancy.

3. What lifestyle changes can help?

Maintain a balanced diet rich in selenium, avoid alcohol, and ensure adequate vitamin K intake. Avoid medications known to impair bile flow.

4. When should delivery be considered?

Delivery is usually planned at 37–38 weeks if bile acids remain >40 µmol/L or if fetal monitoring indicates distress.

Conclusion

Pregnancy cholestasis, though uncommon, poses significant risks to both mother and baby. Early recognition, prompt laboratory evaluation, and initiation of UDCA therapy can alleviate maternal symptoms and potentially reduce adverse fetal outcomes. Close monitoring and individualized delivery planning remain essential components of care. Women with a history of cholestasis should receive pre‑conception counseling and early prenatal screening to ensure optimal outcomes in future pregnancies.